Cost-utility analysis of mogamulizumab in advanced mycosis fungoides and Sezary syndrome cutaneous T-cell lymphoma.

ABSTRACT: Aim: This study assessed the cost-utility of mogamulizumab, a novel monoclonal antibody, versus established clinical management (ECM) in UK patients in previously treated advanced mycosis fungoides (MF)/Sézary syndrome (SS). Materials & methods: Lifetime partitioned survival model based on overall survival, next treatment-free survival and the use of allogeneic stem cell transplant was developed. Inputs were from the pivotal MAVORIC trial, real-world evidence and published literature. Extensive sensitivity analyses were conducted. Results: Discounted incremental quality-adjusted life years (QALYs), costs and incremental cost-effectiveness ratio were 3.08, £86,998 and £28,233. Results were most sensitive to the survival extrapolations, utilities and costs after loss of

SUBMITTER: Muszbek N 

PROVIDER: S-EPMC10508303 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature